Memphis Pharmaceuticals results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit14.9 millionEGP · +6.4% vs the same period a year earlier
Total assets587 millionEGP · +35.3% vs the same period a year earlier
Shareholders' equity58.56 millionEGP · +298.2% vs the same period a year earlier
Operating cash flow-3.47 millionEGP · +33.9% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q2 2023 was about 14.9 million EGP, up +6.4% from 14 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 587 million EGP, and shareholders' equity about 58.56 million EGP.
- Operating cash flow for Q2 2023 was negative at 3.47 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit14.9 million14 million+6.4%
Gross profit55.79 million49.4 million+12.9%
Total assets587 million434 million+35.3%
Total liabilities528 million463 million+14.0%
Shareholders' equity58.56 million-29.54 million+298.2%
Total liabilities and equity587 million434 million+35.3%
Operating cash flow-3.47 million-5.25 million+33.9%
Investing cash flow-991 thousand-1.4 million+29.3%
Financing cash flow2.34 million——
Net change in cash-2.11 million-6.65 million+68.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy